首页> 外文OA文献 >Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments
【2h】

Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments

机译:中国2型糖尿病:教育和研究合作伙伴以评估新的抗糖尿病治疗方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There are 40 million people with diabetes in China, and the projected increase in the rates of obesity and premature cardiovascular disease is alarming. Most patients prefer to combine traditional Chinese medicine with Western medicine, but there is little or no information about the risks and benefits of this approach. Traditional Chinese medicine identifies three patterns of ‘depletion–thirst’ syndrome and therapy is aimed at reversing the deficiency in yin and qi, using a combination of products tailored to the symptoms and clinical features of individual patients. In Western medicine a number of new oral and injectable antidiabetic therapies are likely to enter routine clinical practice over the next 5 years, for example long-acting GLP-1 analogues, DPP-IV inhibitors and dual PPAR-α, PPAR-γ agonists. To make best use of these agents in China and to promote diabetes education and health service development, there is a need for improved communication and collaboration between universities and hospitals both inside and outside China; and Western pharmacologists and clinicians need a better understanding of traditional Chinese medicine. There are several examples of institutional cooperation that should further diabetes research in China, for example the Beijing Chaoyang Diabetes Hospital linked with Imperial College, London, and the University of Nottingham, which has a new campus in Ningbo, south of Shanghai.
机译:中国有4000万人患有糖尿病,而且肥胖症和过早的心血管疾病的发病率预计还会增加。大多数患者倾向于将中药与西药结合使用,但很少或没有关于这种方法的风险和益处的信息。传统中药识别出三种类型的“口渴-口渴”综合症,治疗的目的是通过针对个别患者的症状和临床特征量身定制的产品来逆转阴虚和气虚。在西医中,许多新的口服和可注射抗糖尿病疗法可能会在未来5年进入常规临床实践,例如长效GLP-1类似物,DPP-IV抑制剂和双重PPAR-α,PPAR-γ激动剂。为了在中国充分利用这些药物并促进糖尿病教育和卫生服务的发展,需要改善中国境内外大学与医院之间的沟通与合作;西方药理学家和临床医生需要更好地了解中药。有几个机构合作的例子可以在中国进一步开展糖尿病研究,例如,与伦敦帝国理工学院相连的北京朝阳糖尿病医院,以及在上海以南的宁波设有新校区的诺丁汉大学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号